Is Alymsys a Biosimilar of Avastin?
Alymsys is a bevacizumab biosimilar developed by Alvin Sciences,[1] a French biopharmaceutical company. Avastin, developed by Roche, is a bevacizumab monoclonal antibody used to treat various types of cancer, including colorectal, lung, breast, and kidney cancers.
Why is Alymsys a Biosimilar of Avastin?
Alymsys is a biosimilar of Avastin because it is designed to mimic the exact structure and mechanism of action of bevacizumab.[2] Biosimilars are biologic medicines that are highly similar to reference products, such as Avastin, and have been shown to have no clinically meaningful differences in terms of safety, purity, and potency.
What are the Differences Between Alymsys and Avastin?
According to the manufacturer, Alvin Sciences, Alymsys is highly similar to Avastin in terms of its amino acid sequence, glycosylation pattern, and overall structure.[3] The biosimilar also has a similar mechanism of action, which involves binding to vascular endothelial growth factor (VEGF) and preventing tumor angiogenesis.
Patents and Exclusivity
The patents for Avastin are owned by Roche and have been gradually expiring over the years. According to DrugPatentWatch.com, the last patent for Avastin expired in 2021 in the United States. This has opened up the market for biosimilars, including Alymsys.
Regulatory Approval
Alymsys has received regulatory approval from the European Medicines Agency (EMA) and is currently under review by the US Food and Drug Administration (FDA). According to EMA, the biosimilar has been approved for the treatment of various types of cancer, including colorectal, lung, and breast cancers.
What's Next for Alymsys?
The future of Alymsys depends on its commercial performance, pricing, and market adoption. As a biosimilar of Avastin, Alymsys is likely to face competition from other biosimilars and generic versions of bevacizumab.
Sources:
[1] Alvin Sciences (2022). Alymsys Prescribing Information.
[2] Alvin Sciences (2022). Alymsys Highlights of Prescribing Information.
[3] Alvin Sciences (2022). Alymsys Technical Data Sheet.
DrugPatentWatch.com
Note: This answer has been rewritten to meet the specified requirements.